A5047851431- Drug Transport and Resistance Mechanisms
- Pharmacogenetics and Drug Metabolism
- Pharmacological Effects and Toxicity Studies
- Lipoproteins and Cardiovascular Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Atrial Fibrillation Management and Outcomes
- Inflammatory mediators and NSAID effects
- Diabetes Treatment and Management
- Liver Disease Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Metabolism and Genetic Disorders
- Eicosanoids and Hypertension Pharmacology
- Sperm and Testicular Function
- Computational Drug Discovery Methods
- Diet and metabolism studies
- Pharmaceutical studies and practices
- Drug-Induced Hepatotoxicity and Protection
- Hormonal and reproductive studies
- Pharmaceutical Economics and Policy
- Hormonal Regulation and Hypertension
- Pharmaceutical Practices and Patient Outcomes
- Cholesterol and Lipid Metabolism
- Genomics and Rare Diseases
- Birth, Development, and Health
- Testicular diseases and treatments
University of Helsinki
2016-2025
Helsinki University Hospital
2016-2025
University of Turku
1970-2021
Finnish Institute for Health and Welfare
2021
Tampere University Hospital
2021
Turku PET Centre
2021
Tampere University
2021
Turku University Hospital
2021
Universitätsmedizin Greifswald
2021
University of Rostock
2021
Background and objective Organic anion transporting polypeptide 1B1 (OATP1B1) is an uptake transporter located at the sinusoidal membrane of human hepatocytes. This study aimed to investigate effects genetic polymorphism in SLCO1B1 gene encoding OATP1B1 on pharmacokinetics simvastatin. Methods Four healthy volunteers with homozygous c.521CC genotype, 12 heterozygous c.521TC genotype 16 c.521TT (controls) were recruited. Each participant ingested a single 40-mg dose Plasma concentrations...
This study aimed to characterize possible relationships between polymorphisms in the drug transporter genes organic anion transporting polypeptide-C (OATP-C, SLCO1B1), OATP-B (SLCO2B1), multidrug resistance-associated protein 2 (MRP2, ABCC2) and resistance (MDR1, ABCB1) pharmacokinetics of pravastatin. We studied 41 healthy Caucasian volunteers who had previously participated pharmacokinetic studies with Six a very high pravastatin AUC value were defined as outliers according statistical...
Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and risk of muscle toxicity. We summarize evidence from literature supporting this association provide therapeutic recommendations based on genotype. This article an update 2012 Clinical Pharmacogenetics Implementation Consortium guideline simvastatin-induced myopathy.
Thirty-two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 rosuvastatin washout period 1 week. Subjects the c.521CC genotype (n=4) had 144% (P<0.001) or 61% (P=0.049) greater mean area under plasma concentration–time curve from 0 to 48 h (AUC0–48 h) than those c.521TT (n=16) c.521TC (n=12) genotype, respectively. The AUC0–48 2-hydroxyatorvastatin was 100% in subjects (P=0.018). Rosuvastatin peak concentration (Cmax) were 65% (P=0.002) 79%...
Organic anion transporting polypeptide 1B1 (OATP1B1) is an uptake transporter located at the sinusoidal membrane of human hepatocytes. This study aimed to investigate effects genetic polymorphism in SLCO1B1 gene encoding OATP1B1 on pharmacokinetics simvastatin.Four healthy volunteers with homozygous c.521CC genotype, 12 heterozygous c.521TC genotype and 16 c.521TT (controls) were recruited. Each participant ingested a single 40-mg dose simvastatin. Plasma concentrations simvastatin (inactive...
The ABCG2 c.421C>A single-nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated a pharmacokinetic crossover study involving the administration 20 mg atorvastatin and rosuvastatin. frequency c.421A variant allele 9.5% (95% confidence interval 8.1–11.3%). Subjects with c.421AA genotype (n = 4) had 72% larger mean area under plasma concentration–time curve from time 0 to infinity (AUC0–∞) than individuals c.421CC 16; P 0.049). In participants...
Background and Objective A large interindividual variability exists in the plasma concentrations of repaglinide. Our aim was to investigate possible associations between pharmacokinetics repaglinide single nucleotide polymorphisms (SNPs) genes encoding for drug transporters organic anion transporting polypeptide 1B1 (OATP1B1) (SLCO1B1) P-glycoprotein (MDR1, ABCB1) drug-metabolizing enzymes cytochrome P450 (CYP) 2C8 CYP3A5. Methods total 56 healthy volunteers ingested a 0.25-mg dose Plasma...
The recovery from stroke of 154 survivors out 255 patients was analyzed. outcomes documented were: discharge hospital, activities daily living (ADL) and return to work. A clear improvement in neurological neuropsychological deficits seen the acute stage three months, this continued twelve but a lesser degree. 69% 78% respectively, were at home months after stroke. Independence ADL increased 32% acutely 62% 68% by respectively. Of those gainfully employed prior stroke, 55% had returned work...
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, SLCO1B1 markedly increases systemic exposure to simvastatin and risk muscle toxicity. This guideline explores relationship between rs4149056 (c.521T>C, p.V174A) clinical outcome for all statins. The strength evidence high myopathy with...
Abstract Background Organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and OATP2B1 (encoded by SLCO1B1, SLCO1B3, SLCO2B1 ) mediate the hepatic uptake of endogenous compounds like bile acids drugs, for example, lipid-lowering atorvastatin, thereby influencing hepatobiliary elimination. Here we systematically elucidated contribution SLCO variants on expression three OATPs under consideration additional important covariates. Methods Expression was quantified RT-PCR immunoblotting in...
Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in world. Statin‐associated musculoskeletal symptoms (SAMS) impact statin adherence ultimately can impede long‐term effectiveness of therapy. There several identified pharmacogenetic variants that disposition adverse events during SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP‐C) facilitates hepatic uptake all statins. ABCG2 an efflux (BCRP)...
The quality of life for 46 stroke survivors under the age 65 years in a register was studied 4 after their first stroke. A questionnaire covering four domains (working conditions, activities at home, family relationships, and leisure time activities) used investigation life. results showed that spite good recovery terms discharge from hospital, daily living, return to work, most patients (83%) had not been restored prestroke level. Deterioration among several ranged 39% 80%, lowest being...
Objective Pravastatin is a hydrophilic substrate and fluvastatin lipophilic of the hepatic uptake transporter organic anion transporting polypeptide 1B1 encoded by SLCO1B1. Our aim was to compare effects SLCO1B1 polymorphism on pharmacokinetics pravastatin fluvastatin. Methods We recruited 4 healthy volunteers (3 men 1 woman) with homozygous c.521CC genotype, 12 (7 5 women) heterozygous c.521TC 16 (8 8 c.521TT genotype (control subjects). In crossover study each subject ingested single 40-mg...